|
[1]OTT JJ,STEVENS GA,GROEGER J,et al.Global epidemiology of hepatitis B virus infection:new estimates of agespecific HBs Ag seroprevalence and endemicity[J].Vaccine,2012,30(12):2212-2219.
|
|
[2]LOZANO R,NAGHAVI M,FOREMAN K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2012,380(9859):2095-2128.
|
|
[3]LIANG X,BI S,YANG W,et al.Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47):6550-6557.
|
|
[4]LIANG X,BI S,YANG W,et al.Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J].J Infect Dis,2009,200(1):39-47.
|
|
[5]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
|
|
[6] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[7]CHANG TT,LAI CL,YOON SK,et al.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2010,51(2):422-430.
|
|
[8]MARCELLIN P,GANE EJ,FLISIAK R,et al.Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance:8 year results from two phase 3 trials[J].Hepatology,2014,60:313a-314a.
|
|
[9]LAU GK,PIRATVISUTH T,LUO KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2005,352(26):2682-2695.
|
|
[10]MARCELLIN P,LAU GK,BONINO F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2004,351(12):1206-1217.
|
|
[11]TENNEY DJ,ROSE RE,BALDICK CJ,et al.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J].Hepatology,2009,49(5):1503-1514.
|
|
[12]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(3):886-893.
|
|
[13]LOK AS.Hepatitis:long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.
|
|
[14]MARCELLIN P,GANE E,BUTI M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.
|
|
[15]FUNG S,KWAN P,FABRI M,et al.Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B[J].Gastroenterology,2014,146(4):980-988.
|
|
[16]LIM YS,YOO BC,BYUN KS,et al.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure:results of a randomised trial[J].Gut,2015,65(6):1042-1051.
|
|
[17]PATTERSON SJ,GEORGE J,STRASSER SI,et al.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B[J].Gut,2011,60(2):247-254.
|
|
[18]BERG T,ZOULIM F,MOELLER B,et al.Long-term efficacy and safety of emtricitabine plus tenofovir DF vs.tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients[J].J Hepatol,2014,60(4):715-722.
|
|
[19]SUNG JJ,LAI JY,ZEUZEM S,et al.Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeA g-positive chronic hepatitis B[J].J Hepatol,2008,48(5):728-735.
|
|
[20]KEEFFE EB,ZEUZEM S,KOFF RS,et al.Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B[J].Clin Gastroenterol Hepatol,2007,5(8):890-897.
|
|
[21]XIE Q,SUN J,TAN D,et al.5-year treatment with telbivudine optimization strategy for chronic hepatitis B shows sustained viral suppression and low resistance to telbivudine[J].Hepatol Int,2016,10:s451-s452.
|
|
[22]LOK AS,TRINH H,CAROSI G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na6ve patients with chronic hepatitis B[J].Gastroenterology,2012,143(3):619-628.
|
|
[23]PIRATVISUTH T,LAU G,CHAO YC,et al.Sustained response to peginterferon alfa-2a(40 k D)with or without lamivudine in Asian patients with HBeA g-positive and HBeA g-negative chronic hepatitis B[J].Hepatol Int,2008,2(1):102-110.
|
|
[24]MARCELLIN P,BONINO F,LAU GK,et al.Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a[J].Gastroenterology,2009,136(7):2169-2179.
|
|
[25]LAMPERTICO P,VIGANO M,di COSTANZO GG,et al.Randomised study comparing 48 and 96 weeks peginterferonα-2a therapy in genotype D HBeA g-negative chronic hepatitis B[J].Gut,2013,62(2):290-298.
|
|
[26]SUN J,MA H,XIE Q,et al.Response-guided peginterferon therapy in patients with HBeA g-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol,2016,65(4):674-682.
|
|
[27]JANSSEN HL,van ZONNEVELD M,SENTURK H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeA g-positive chronic hepatitis B:a randomised trial[J].Lancet,2005,365(9454):123-129.
|
|
[28]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined pegylated interferon alfa-2a(40KD)and entecavir treatment for hepatitis B“e”antigen-positive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723.
|
|
[29]MARCELLIN P,AHN SH,MA X,et al.Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J].Gastroenterology,2016,150(1):46-60.
|
|
[30]FAN R,SUN J,HOU J.Combination therapy with tenofovir and peginterferon may not be translated into current clinical practice[J].Gastroenterology,2016,150(5):1253-1254.
|
|
[31]PAN CQ,DUAN Z,DAI E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J].N Engl J Med,2016,374(24):2324-2334.
|
DownLoad: